Novelion Therapeutics Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2018. GAAP total net revenues for the fourth quarter of 2018 were $40.7 million compared to $38.9 million for the same period in 2017. GAAP net loss in the fourth quarter of 2018 was $19.4 million, an improvement of approximately 21.1% compared to GAAP net loss of $24.6 million during the same period in 2017. Income from operations was $1,031,000 compared to loss of $13,964,000 a year ago. Basic and diluted net loss per common share was $1.03 compared to $1.32 a year ago. GAAP total net revenues for the year ended December 31, 2018 were $130.4 million compared to $138.4 million for 2017. GAAP net loss for the year ended December 31, 2018 was $108.3 million compared to GAAP net loss of $126.7 million for 2017. Loss from operations was $50,067,000 compared to loss of $86,798,000 a year ago. Basic and diluted net loss per common share was $5.76 compared to $6.81 a year ago.